Dr. Kelvin Chan is a Medical Oncologist at the Sunnybrook Odette Cancer Centre, a Professor at the University of Toronto, and an associate scientist at the Sunnybrook Research Institute. He has completed both an MSc and a PhD in Biostatistics, and also holds an MSc in Clinical Epidemiology.

Dr. Chan’s research focuses on the different aspects of the value of cancer drugs, including health economics, health technology assessment, and real-world evidence. He is the Co-Director at the Canadian Centre for Applied Research in Cancer Control (ARCC) and the Platform Director of the Canadian Cancer Real-world Evaluation (CCRE) Platform, funded the Post-Marketed Drug Evaluation (PMDE) program at the Canada’s Drug Agency.

Dr. Chan is especially interested in cancer drug reimbursement related issues. He is a member of multiple provincial and national committees related to cancer drug assessments and recommendations including the pan-Canadian Oncology Drug Review (pCODR) Expert Review Committee (pERC), the Committee to Evaluate Drugs (CED) and the Ontario Steering Committee of Cancer Drugs (OSCCD). He was also the Clinical Lead for the Provincial Drug Reimbursement Programs (PDRP) at Ontario Health – Cancer Care Ontario (OH-CCO), from September 2014 to July 2024.

Dr. Vishal Navani leads Calgary’s thoracic oncology clinical trials program and early-phase drug development unit, with a focus on translating innovative science into impactful cancer care. He has served as Principal Investigator on dozens of clinical trials across phases I–III, and sits on several national and international trial steering committees.
As Director of Glans Look Research, he oversees North America’s largest real-world evidence (RWE) database in thoracic malignancies, advancing precision oncology and population-level insights. His research has attracted over $1.5 million in competitive grant funding, including a recent award from the Terry Fox Marathon of Hope Cancer Centres Network for his work in data science and patient reported outcomes.
Dr. Navani is also a recognized thought leader in clinical evidence generation, contributing as a clinical expert to the Canadian Drug Agency (CDA) in support of national drug reimbursement and policy deliberations. In parallel, he collaborates closely with the life sciences sector, providing strategic guidance on clinical development, trial design, and real-world evidence integration. His academic work has been published in leading journals including Journal of Clinical Oncology, JAMA Oncology, and The Lancet Oncology, reflecting a commitment to high-impact, peer-reviewed research at the interface of clinical innovation and patient care.
He holds a MA (Honours) from Oxford, MBBS from London (Imperial College) & is board certified in Canada, Australia & the UK.

Dr. Dylan O’Sullivan is an early-career cancer epidemiologist and health services researcher with a broad research program focused on reducing the burden of cancer across the cancer control continuum. His primary research interests include the etiology of early-onset cancers, risk-stratified approaches to screening, and optimizing screening and follow-up surveillance for subsequent primary cancers among cancer survivors. His research program involves collaborations with researchers across multiple disciplines, including computer scientists, qualitative researchers, molecular epidemiologists, medical oncologists, cancer screening experts, and patient partners. To date, Dr. O’Sullivan has published over 75 peer-reviewed articles in leading scholarly journals and has secured over $4.5 million in grant funding.

Reka Pataky is a Senior Health Economist in the Regulatory Science Lab, led by Dr. Dean Regier at BC Cancer. She holds a PhD from the School of Population and Public Health at the University of British Columbia. Her work focuses on generating real-world evidence of effectiveness, safety, and cost-effectiveness of cancer drugs and programs using large observational datasets, to support decision-making in learning health systems.